GSK-3: a multifaceted player in acute leukemias

Area of Science:

• Biochemistry
• Molecular Biology
• Oncology

Background:

• Glycogen synthase kinase 3 (GSK-3) comprises two isoforms (α and β) with constitutive activity, regulated by upstream phosphorylation.
• Initially recognized for glucose metabolism, GSK-3 is now known to influence diverse cellular signaling pathways.

Purpose of the Study:

• To elucidate the complex and often contradictory roles of GSK-3 isoforms in acute leukemias.
• To review the therapeutic potential of GSK-3 inhibitors in developing novel leukemia treatments.

Main Methods:

• Literature review of GSK-3's involvement in cancer pathophysiology.
• Analysis of GSK-3's regulatory functions in cell cycle, apoptosis, DNA repair, metabolism, invasion, and metastasis.
• Assessment of current GSK-3 inhibitor development for leukemia therapy.

Main Results:

• GSK-3 was initially considered a tumor suppressor due to its role in degrading oncogenic proteins.
• Emerging evidence highlights GSK-3's oncogenic properties, promoting cancer cell proliferation, survival, and drug resistance.
• GSK-3 isoforms exhibit multifaceted roles in acute leukemias, impacting various cancer hallmarks.

Conclusions:

• The dual role of GSK-3 in cancer necessitates careful consideration for therapeutic strategies.
• Targeting GSK-3, particularly in combination therapies, offers a promising avenue for innovative leukemia treatment.